Stockscreener 앱 받기
6.18
0.16%
-0.01
시간 외 거래:
6.18
전일 마감가:
$6.19
열려 있는:
$6.17
하루 거래량:
1.71M
Relative Volume:
0.47
시가총액:
$947.55M
수익:
$418.84M
순이익/손실:
$-1.60M
주가수익비율:
-600.00
EPS:
-0.0103
순현금흐름:
$69.77M
1주 성능:
+0.65%
1개월 성능:
+14.23%
6개월 성능:
-46.59%
1년 성능:
-51.64%
1일 변동 폭
$6.01
$6.25
1주일 범위
$5.81
$6.32
52주 변동 폭
$5.19
$13.88
Certara Inc Stock (CERT) Company Profile
명칭
Certara Inc
전화
(415) 237-8272
주소
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, BTSG, TEM, HQY, DOCS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
6.18 | 949.08M | 418.84M | -1.60M | 69.77M | -0.0103 |
VEEV
Veeva Systems Inc
|
171.19 | 27.80B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
51.44 | 10.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
54.07 | 10.01B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
82.63 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
25.77 | 4.60B | 637.78M | 239.40M | 307.21M | 1.1909 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-06 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-02-27 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2026-01-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-21 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-11-13 | 개시 | BMO Capital Markets | Market Perform |
| 2025-09-29 | 개시 | Craig Hallum | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-08 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-02-27 | 개시 | TD Cowen | Buy |
| 2024-09-27 | 업그레이드 | UBS | Neutral → Buy |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-04-04 | 개시 | JMP Securities | Mkt Perform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | UBS | Neutral |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2023-08-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-08-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-04-12 | 개시 | Stephens | Overweight |
| 2023-04-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-09-08 | 개시 | Berenberg | Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-07-01 | 개시 | Piper Sandler | Overweight |
| 2022-01-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2021-07-23 | 개시 | Robert W. Baird | Outperform |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-01-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Neutral |
| 2021-01-05 | 개시 | Jefferies | Hold |
| 2021-01-05 | 개시 | William Blair | Outperform |
모두보기
Certara Inc 주식(CERT)의 최신 뉴스
Certara (CERT) Sells Regulatory and Medical Writing Business for Up to $135M - Yahoo Finance
Veristat expands with Certara acquisition - BioXconomy
Certara (CERT) price target decreased by 23.74% to 9.63 - MSN
AI in Predictive Toxicology Research Report 2026 Featuring - GlobeNewswire
AI in Predictive Toxicology Research Report 2026 Featuring Certara, Schrodinger, Instem, Simulations Plus, Lhasa, ChemaxonGlobal Forecast to 2030 and 2035 - Yahoo Finance
Certara strategic business divestiture comes at right time, says analyst - MSN
Certara | D: Filing D - Moomoo
Certara, Inc. (NASDAQ:CERT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight - GlobeNewswire Inc.
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates - MSN
Certara to sell regulatory and medical writing business for up to $135M - MSN
How The Certara (CERT) Story Is Shifting As Analysts Recut Targets And Expectations - Yahoo Finance
Wall Street analysts think Certara (CERT) could surge 43.28%: Read this before placing a bet - MSN
Certara: An Interesting Situation To Keep Track Off (NASDAQ:CERT) - Seeking Alpha
CERT Price Today: Certara, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
(CERT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Barclays Remains a Hold on Certara (CERT) - The Globe and Mail
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst - Sahm
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report? - MSN
CERT Certara posts 8.8 percent year-over-year Q4 2025 revenue growth despite sizeable EPS miss pressuring shares.Barrier to Entry - UBND thành phố Hải Phòng
Certara to Divest Regulatory and Medical Writing Business - The Globe and Mail
Certara to sell regulatory writing unit to Veristat for $135M By Investing.com - Investing.com India
Is Certara (CERT) stock considered stable (+2.26%) 2026-04-22Price Surge - Cổng thông tin điện tử tỉnh Lào Cai
Certara (CERT) Sells Regulatory Writing Business for Up to $135 Million - GuruFocus
Veristat to Acquire Certara’s Regulatory and Medical Writing Business - Business Wire
William Blair Maintains Certara(CERT.US) With Hold Rating - Moomoo
Veristat, LLC signed a definitive agreement to acquire Regulatory and Medical Writing business of Certara, Inc for approximately $140 million. - marketscreener.com
Craig-Hallum Initiates Certara(CERT.US) With Hold Rating - Moomoo
Certara Shares Rise Amid Plan to Sell Portion of Business to Veristat - Moomoo
Certara to Sell Regulatory and Medical Writing Business to Veristat for Up to $135 Million, Refocuses on Model-Informed Drug Development 1 - Minichart
Certara to sell regulatory writing unit to Veristat for $135M - Investing.com
Certara to Sell Regulatory, Medical Writing Business to Veristat for $135 Million - marketscreener.com
Certara : Regulatory and Medical Writing – Supplemental Information - marketscreener.com
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat - The Manila Times
Certara to Sell Global Medical Writing Business to Veristat for $100M, Plus Up to $35M Earn-Out - TradingView
Certara (NASDAQ: CERT) divests regulatory and medical writing unit to Veristat - Stock Titan
Analysts Conflicted on These Healthcare Names: Vivos Therapeutics (VVOS), Certara (CERT) and Option Care Health (OPCH) - The Globe and Mail
Certara, Inc. $CERT Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Certara Inc (CERT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.66%
1.60%
자본화:
|
볼륨(24시간):